Reviva Pharmaceuticals Holdings Inc (RVPHW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc (RVPHW) has a cash flow conversion efficiency ratio of -1.229x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.59 Million) by net assets ($4.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Reviva Pharmaceuticals Holdings Inc for the company's overall valuation and market capitalisation.
Reviva Pharmaceuticals Holdings Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Reviva Pharmaceuticals Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Reviva Pharmaceuticals Holdings Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lion Financial Group Limited
NASDAQ:LGHLW
|
-0.504x |
|
Prairie Lithium Limited
AU:PL9
|
-0.077x |
|
Liberty Metals Ltd
AU:LIB
|
N/A |
|
US Solar Fund PLC
LSE:USFP
|
-0.007x |
|
Advent Technologies Holdings Inc
NASDAQ:ADNWW
|
-0.015x |
|
Kardan NV
TA:KRNV
|
-0.001x |
|
Arko Corp
NASDAQ:ARKOW
|
0.132x |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
-0.108x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc from 2018 to 2024. View RVPHW stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more